Biomarkers in lung cancer

Frontiers in Bioscience - Elite

Volumn 2 E, Issue 3, 2010, Pages 1099-1104

  Bearz, Alessandra ^a   Berretta, Massimiliano ^a   Cappellani, Alessandro ^b   Lleshi, Arben ^a   Berto, Eleonora ^a   Fratino, Lucia ^a   Tirelli, Umberto ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

Cancer; Lung; Markers; Review; Tumor

Indexed keywords

EID: 84883285165     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: 10.2741/e168     Document Type: Review

References (55)

1. F. Kamangar, G. M. Dores and W. F. Anderson: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24, 2137-2150 (2006) (Pubitemid 46655601)
2. G. D'Addario and E. E. Felip, ESMO Guidelines Working Group: Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4), 68-70 (2009)
3. D. M. Parkin, F. Bray, J. Ferlay and P. Pisani: Global cancer statistics, 2002. CA Cancer J Clin 55, 74-108 (2005) (Pubitemid 40372904)
4. Pathology and genetics of tumors of the lung, pleura, thymus and heart. IARC Press 2004
5. P. Ceppi, M. Volante, S. Saviozzi, I. Rapa, S. Novello, A. Cambieri, M. Lo Iacono, S. Cappia, M. Papotti and G. V. Scagliotti: Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 107, 1589-1596 (2006) (Pubitemid 44546920)
6. L. G. Jørgensen, K. Osterlind, J. Genollá, S. A. Gomm, J. R. Hernández, P. W. Johnson, J. Løber, T. A. Splinter and M. Szturmowicz: Serum neuron-specific enolase (S-NSE) and the prognosis in small cell lung cancer (SCLC): a combined multivariate analysis on data from nine centers. Br J Cancer 74, 463-467 (1996) (Pubitemid 26254580)
7. V. Macchia, A. Mariano, M. Cavalcanti, A. Coppa, C. Cecere, G. Fraioli, S. Elia and G. Ferrante: Tumor markers and lung cancer: correlation between serum and bronchial secretion levels of CEA, TPA, Can Ag Ca-50, NSE and ferritin. Int J Biol Markers 2, 151-156 (1987)
8. J. L. Pujol, X. Quantin, M. Jacot, J. M. Boher, J. Grenier and P. J. Lamy: Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer. Lung Cancer 39, 131-138 (2003) (Pubitemid 36173612)
9. L. Viberti, M. Bongiovanni, S. Croce and G. Bussolati: 34bE12 Cytokeratin immunodetection in the differential diagnosis of small cell tumors of lung. Int J Surg Pathol 8, 317-322 (2000) (Pubitemid 32120693)
10. D. N. Carney, P. J. Marangos, D. C. Ihde, P. A. Bunn Jr, M. H. Cohen, J. D. Minna and A. F. Gazdar: Serum neuronspecific enolase a marker for disease extent and response to therapy for small-cell lung cancer. Lancet 1, 583-585 (1982) (Pubitemid 12171820)
11. T. Shibayama, T. Ohnoshi, H. Ueoka, T. Horiguchi, T. Kodani, Y. Segawa, T. Maeda, K. Miyatake, N. Takigawa and I. Kimura: Serum neuron specific enolase (NSE) in patients with non small cell lung cancer. Nihon Kyobu Shikkan Gakkai Zasshi 30, 1097-1102 (1992)
12. F. R. Nobels, D. J. Kwekkeboom, W. Coopmans, C. H. Schoenmakers, J. Lindemans, W. W. De Herder, E. P. Krenning, R. Bouillon and S. W. Lamberts: Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alphasubunit of glycoprotein hormones. J Clin Endocrinol Metab 82, 2622-2628 (1997) (Pubitemid 27337883)
13. L. Drivsholm, L. I. Paloheimo and K Osterlind: Chromogranin A, a significant prognostic factor in small cell lung cancer. Br J Cancer 81, 667-671 (1999) (Pubitemid 29458863)
14. J. L. Pujol, J. Grenier, E. Parrat, M. Lehmann, T. Lafontaine, X. Quantin and F. B. Michel: Cytokeratins as serum markers in lung cancer: a comparison of Cyfra 21-1 and TPS. Am J Resp Crit Care Med 154, 725-733 (1996) (Pubitemid 26327298)
15. European Group on Tumor Markers: Consensus recommendations. Anticancer Res 19, 2785-2820 (1999)
16. J. Schneider, N. Bitterlich, H. G. Velcovsky, H. Morr, N. Katz and E. Eigenbrodt: Fuzzy logic-based tumor marker profiles improved sensitivity in the diagnosis of lung cancer. Int J Clin Oncol 7, 145-151 (2002) (Pubitemid 34733479)
17. R. Molina, X. Filella, J. M. Augé, R. Fuentes, I. Bover, J. Rifa, V. Moreno, E. Canals, N. Vinoals, A. Marquez, E. Barreiro, J. Borras and P. Viladiu. Tumor markers (CEA, Ca 125, Cyfra 21-1, SCC and NSE) in NSCLC patients as aid in histological diagnosis and prognostic: comparison with the main clinical, pathological and anthropomorphic prognostic factors. Tumor Biol 24, 209-218 (2003) (Pubitemid 37500571)
18. J. L. Pujol, J. M. Boher, J. Grenier and X. Quantin: Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Lung Cancer 31, 221-231 (2001) (Pubitemid 32109238)
19. R. Molina, J. M. Auge, J. M. Escudero, R. Marrades, N. Vinolas, E. Carcereny, J. Ramirez, X. Filella: Mucins Ca 125, Ca 19.9., Ca 15-3 and TAG 72.3. as tumor markers in patients with lung cancer: comparison with Cyfra 21.1., CEA, Scc and NSE. Tumor Biol 29, 371-380 (2008)
20. A. López-Ferrer, V. Curull, C. Barranco, M. Garrido, J. Lloreta, F. X. Real and C. de Bolós: Mucins as differentiation markers in bronchial epithelium. Squamous cell carcinoma and adenocarcinoma display similar expression patterns. Am J Respir Cell Mol Biol 24, 22-29 (2001) (Pubitemid 32097504)
21. D. F. Hayes, V. R. Zurawski and D. W. Kufe: Comparison of circulating Ca 15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol 10, 1542-1550 (1986) (Pubitemid 17183580)
22. D. Hayes, H. Sekine, T. Ohao, M. Abe, K. Keefe and D. W. Kufe: Use of murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. J Clin Invest 75, 1671-1678 (1985) (Pubitemid 15039493)
23. D. F. Hayes, V. R. Zurawski and D. W. Kufe: Comparison of circulating Ca15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol 10, 1542-1550 (1986) (Pubitemid 17183580)
24. D. M. F. Pons-Anicet, B. P. Krebs and M. Namer: Value of Ca15-3 in the follow-up of breast cancer patients. Br J Surg 55, 567-569 (1987) (Pubitemid 17098869)
25. C. Todini, D. F. Hayes, R. Gelman, I. C. Henderson and D. Kufe: Comparison of Ca15-3 and carcinoembryonic antigen in monitoring of the clinical course of patients with metastatic breast cancer. Cancer Res 48, 41107-41112 (1988)
26. J. Wesseling, S. W. van der Valk and J. Hilkens: A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol Biol Cell 7, 565-577 (1996) (Pubitemid 26112564)
27. F. Guddo, A. Giatromanolaki, M. I. Koukourakis, C. Reina, A. M. Vignola, G. Chlouverakis, J. Hilkens, K. C. Gatter, A. L. Harris and G Bonsignore: MUC-1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients. J Clin Pathol 51, 667-671 (1998) (Pubitemid 28423725)
28. J. A. Jarrard, R. I. Linnoila, H. Lee, S. M. Steinberg, H. Witschki and E. Szabo: MUC-1 is a novel marker for the type II pneumocyte lineage during lung carcinogenesis. Cancer Res 58, 5582-5589 (1998) (Pubitemid 28551149)
29. A. Bearz, R. Talamini, E. Vaccher, M. Spina, C. Simonelli, A. Steffan, M. Berretta, E. Chimienti, U. Tirelli: MUC-1 (CA 15-3 antigen) as a highly reliable predictor of response to EGFR inhibitors in patients with bronchioloalveolar carcinoma: an experience on 26 patients. Int J Biol Markers 22, 307-311 (2007) (Pubitemid 351256268)
30. T. Muley, T. H. Fetz, H. Dienemann, H. Hoffmann, F. J. Herth, M. Meister and W. Ebert: Tumor volume and tumor marker index based on CYFRA 21-1 and CEA are strong prognostic factors in operated early stage NSCLC. Lung Cancer 60, 408-415 (2008)
31. F. Blankenburg, R. Hatz, D. Nagel, D. Ankerst, J. Reinmiedl, C. Gruber, D. Seidel and P. Stieber: Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer: external validation of a prognostic score. Tumour Biol 29, 272-277 (2008)
32. J. Niklinski, M. Furman, J. Laudanski and M. Kozlowski: Prognostic value of pretreatment CEA, SCCAg and CA 19-9 levels in sera of patients with non-small cell lung cancer. Eur J Cancer Prev 1, 1401-1406 (1992)
33. K. Kagohashi, H. Satoh, H. Ishikawa, M. Ohtsuka and K. Sekizawa: A re-evaluation of squamous cell carcinoma antigen (SCC) as a serum marker for non-small cell lung cancer. Med Oncol 25, 187-189 (2008)
34. M. Volker, M. J. Mone, P. Karmakar, A. van Hoffen, W. Schul, W. Vermeulen, J. H. Hoeijmakers, R. van Driel, A. A. van Zeeland and L. H. Mullenders: Sequential assembly of the nucleotide excision repair factors in vivo. Molec Cell 8, 213-224 (2001) (Pubitemid 32772919)
35. G. R. Simon, S. Sharma, A. Cantor, P. Smith and G. Bepler: ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 127, 978-983 (2005) (Pubitemid 40775532)
36. R. V. Lord, J. Brabender, D. Gandara, V. Alberola, C. Camps, M. Domine, F. Cardenal, J. M. Sánchez, P. H. Gumerlock, M. Tarón, J. J. Sánchez, K. D. Danenberg, P. V. Danenberg and R. Rosell: Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8, 2286-2291 (2002) (Pubitemid 34753602)
37. K. Olaussen, A. Dunant, P. Fouret, E. Brambilla, F. André, V. Haddad, E. Taranchon, M. Filipits, R. Pirker, H. H. Popper, R. Stahel, L. Sabatier, J. P. Pignon, T. Tursz, T. Le Chevalier and J. C Soria; IALT Bio Investigators: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. Engl J Med 355, 983-991 (2006) (Pubitemid 44343542)
38. J. Stubbe: Ribonucleotide reductase in the twenty-first century: Proc Natl Acad Sci USA 95, 2723-2724 (1998)
39. C. Reynolds, C. Obasaju, M. J. Schell, X. Li, Z. Zheng, D. Boulware, J. R. Caton, L. C. Demarco, M. A. O'Rourke, G. Shaw Wright, K. A. Boehm, L. Asmar, J. Bromund, G. Peng, M. J. Monberg and G. Bepler: Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 27, 5808-5815 (2009)
40. S. Lafarge, V. Sylvain, M. Ferrara and Y. J. Bignon: Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 20, 6597-6606 (2001) (Pubitemid 32980286)
41. A. Husain, G. He, E. S. Venkatraman and D. R. Spriggs: BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum (II). Cancer Res 58, 1120-1123 (1998) (Pubitemid 28183195)
42. A. Bhattacharyya, U. S. Ear, B. H. Koller, R. R. Weichselbaum and D. K. Bishop: The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 275, 23899-23903 (2000) (Pubitemid 30624678)
43. A. Potti, S. Mukherjee, R. Peterson, H. K. Dressman and A. Bild: A genomic strategy to refine prognosis in early stage non-small cell lung cancer. N Engl J Med 355, 570-580 (2006) (Pubitemid 44200650)
44. R. Rosell, M. Skrzypski, E. Jassem, M. Taron, R. Bartolucci, J. J. Sanchez, P. Mendez, I. Chaib, L. Perez-Roca, A. Szymanowska, W. Rzyman, F. Puma, G. Kobierska-Gulida, F. Farabi and J. Jassem: BRCA1: a novel prognostic factor in resected non-small cell lung cancer. PLoS One 2, e1129 (2007)
45. J. Schlessinger: Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 110, 669-672 (2002) (Pubitemid 35283957)
46. C. L. Arteaga: Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 29(Suppl 14), 3-9 (2002) (Pubitemid 35191041)
47. R. S. Herbst and P. A. Bunn Jr: Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res 9, 5813-5824 (2003) (Pubitemid 38018062)
48. T. J. Lynch, D. W. Bell, R. Sordella, S. Gurubhagavatula, R. A. Okimoto, B. W. Brannigan, P. L. Harris, S. M. Haserlat, J. G. Supko, F. G. Haluska, D. N. Louis, D. C. Christiani, J. Settleman and D. A. Haber: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350, 2129-2139 (2004) (Pubitemid 38637993)
49. J. G. Paez, P. A. Jänne, J. C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F. J. Kaye, N. Lindeman, T. J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M. J. Eck, W. R. Sellers, B. E. Johnson and M. Meyerson: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004) (Pubitemid 38720929)
50. T. S. Mok, Y. L. Wu, C. J. Yu, C. Zhou, Y. M. Chen, L. Zhang, J. Ignacio, M. Liao, V. Srimuninnimit, M. J. Boyer, M. Chua-Tan, V. Sriuranpong, A. W. Sudoyo, K. Jin, M. Johnston, W. Chui and J. S. Lee: Randomized, placebocontrolled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced nonsmallcell lung cancer. J Clin Oncol 27, 5080-5087 (2009)
51. M. S. Tsao, A. Sakurada, J. C. Cutz, C. Q. Zhu, S. Kamel-Reid, J. Squire, I. Lorimer, T. Zhang, N. Liu, M. Daneshmand, P. Marrano, G. da Cunha Santos, A. Lagarde, F. Richardson, L. Seymour, M. Whitehead, K. Ding, J. Pater and F. A. Shepherd: Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 353, 133-144 (2005) (Pubitemid 41058345)
52. H. Linardou, I. J. Dahabreh, D. Kanaloupiti, F. Siannis, D. Bafaloukos, P. Kosmidis, C. A. Papadimitriou and S. Murray: Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9, 962-972 (2008)
53. P. Stephens, C. Hunter, G. Bignell, S. Edkins, H. Davies, J. Teague, C. Stevens, S. O'Meara, R. Smith, A. Parker, A. Barthorpe, M. Blow, L. Brackenbury, A. Butler, O. Clarke, J. Cole, E. Dicks, A. Dike, A. Drozd, K. Edwards, S. Forbes, R. Foster, K. Gray, C. Greenman, K. Halliday, K. Hills, V. Kosmidou, R. Lugg, A. Menzies, J. Perry, R. Petty, K. Raine, L. Ratford, R. Shepherd, A. Small, Y. Stephens, C. Tofts, J. Varian, S. West, S. Widaa, A. Yates, F. Brasseur, C. S. Cooper, A. M. Flanagan, M. Knowles, S. Y. Leung, D. N. Louis, L. H. Looijenga, B. Malkowicz, M. A. Pierotti, B. Teh, G. Chenevix-Trench, B. L. Weber, S. T. Yuen, G. Harris, P. Goldstraw, A. G. Nicholson, P. A. Futreal, R. Wooster and M. R. Stratton: Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431, 525-526 (2004)
54. E. E. Cohen, M. W. Lingen, L. E. Martin, P. L. Harris, B. W. Brannigan, S. M. Haserlat, R. A. Okimoto, D. C. Sgroi, S. Dahiya, B. Muir, J. R. Clark, J. W. Rocco, E. E. Vokes, D. A. Haber and D. W. Bell: Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res 11, 8105-8108 (2005) (Pubitemid 41698754)
55. F. Hirsch, M. Varella-Garcia and F. Cappuzzo: Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene 28(Suppl 1), S32-37 (2009)